Management of Patient with eGFR 44 mL/min/1.73 m²
This patient has CKD Stage 3b (moderate to severe GFR decrease), which requires comprehensive management focused on slowing progression, managing complications, and preparing for potential renal replacement therapy. 1
Classification and Risk Stratification
- eGFR of 44 mL/min/1.73 m² places this patient in CKD Stage 3b (30-44 mL/min/1.73 m²), indicating moderate to severe kidney function decline 1
- Stage 3b CKD carries significantly increased cardiovascular risk and mortality, with hazard ratios exceeding 1.4 for cardiovascular disease and over 3-fold increased risk of death compared to earlier stages 2, 3
- Immediate assessment of albuminuria (UACR) is essential to complete risk stratification, as the combination of eGFR and albuminuria determines overall prognosis and treatment intensity 1, 4
Essential Diagnostic Workup
Obtain the following immediately:
- Urinary albumin-to-creatinine ratio (UACR) to assess proteinuria and guide treatment decisions 1
- Complete metabolic panel including serum electrolytes, calcium, phosphate, and bicarbonate to screen for CKD complications 4
- Complete blood count to evaluate for anemia 4
- Parathyroid hormone (PTH) and vitamin D levels to assess for metabolic bone disease 4
- Lipid panel for cardiovascular risk assessment 1
- Hemoglobin A1c if diabetes is present or suspected 1, 5
Blood Pressure Management
Target blood pressure: <140/90 mmHg 6
- If UACR >300 mg/g OR if patient has diabetes with hypertension, initiate ACE inhibitor or ARB as first-line therapy 1
- If UACR 30-300 mg/g with diabetes and hypertension, ACE inhibitors or ARBs are also preferred 1
- Monitor serum potassium and creatinine 1-2 weeks after initiating or adjusting RAAS blockade 4
- Do NOT combine ACE inhibitors with ARBs - this combination increases adverse events without additional benefit 6
Glycemic Control (if diabetic)
For patients with diabetes:
First-line: Metformin is recommended at eGFR 44 mL/min/1.73 m² 5
Second-line: Add SGLT2 inhibitor for renal and cardiovascular protection 5
Third-line: Consider long-acting GLP-1 receptor agonist if glycemic targets not met with metformin and SGLT2i 5
- Prioritize agents with documented cardiovascular benefits (dulaglutide, liraglutide, semaglutide) 5
Dietary Modifications
Protein intake: approximately 0.8 g/kg/day - neither higher nor lower 1, 4
Sodium restriction: reduce intake if currently >3.3 g/day, but routine restriction to <2 g/day is not recommended 6
- Individualize based on blood pressure control and volume status 4
Potassium restriction may be necessary depending on serum potassium levels, particularly with RAAS blockade 4
Monitoring Schedule
At eGFR 44 mL/min/1.73 m², monitor every 6 months (twice yearly): 4
- eGFR and serum creatinine 1, 4
- UACR 1
- Electrolytes, calcium, phosphate 4
- Complete blood count 4
- PTH if abnormal initially 4
Increase monitoring frequency to 3-4 times yearly if: 4
- Albuminuria is in higher categories (UACR >300 mg/g)
- eGFR continues to decline
- Complications develop
Nephrology Referral
Refer to nephrology now - eGFR <45 mL/min/1.73 m² warrants specialist involvement 6
Additional referral indications include:
- UACR >60 mg/mmol or protein excretion >1 g/day 6
- Rapid decline in eGFR (>5 mL/min/1.73 m² per year) 4
- Difficulty managing complications (anemia, bone disease, electrolyte abnormalities) 4
Medication Dosing Adjustments
Review ALL medications and adjust doses based on eGFR of 44 mL/min/1.73 m²: 5, 7
- Calculate absolute clearance (mL/min) by multiplying eGFR by patient's actual body surface area divided by 1.73 6
- Many medications require dose reduction at this level of kidney function 7
- Avoid nephrotoxic agents (NSAIDs, aminoglycosides, contrast agents when possible) 7
Preparation for Progression
While not imminent, begin education about: 1
- Renal replacement therapy options (hemodialysis, peritoneal dialysis, transplantation) should be discussed when eGFR approaches 30 mL/min/1.73 m² 1
- Vascular access planning typically begins when eGFR <20 mL/min/1.73 m² 1
- The average decline in elderly patients is approximately 16.6 mL/min/1.73 m² per decade, though this accelerates with age 3
Critical Pitfalls to Avoid
- Do not ignore this eGFR as "normal for age" - Stage 3b CKD carries substantial morbidity and mortality risk regardless of age 2, 8, 3
- Do not delay nephrology referral - 48.7% of Stage 3 CKD cases are missed by routine screening, and Stage 3b patients have the highest risk (20%) of progressing to renal failure 8
- Do not combine ACE inhibitors with ARBs - this increases harm without benefit 6
- Do not restrict protein below 0.8 g/kg/day - this provides no benefit and may cause malnutrition 4, 6